U.S., Aug. 1 -- ClinicalTrials.gov registry received information related to the study (NCT07739758) titled 'A Study of YL201 in Combination With Serplulimab in Participants With Treatment-naive Extensive-stage Small Cell Lung Cancer' on July 28.
Brief Summary: This trial is a registrational Phase III, randomized, open-label, multicenter study to compare the efficacy and safety of YL201 in combination with serplulimab versus standard-of-care carboplatin and etoposide in combination with serplulimab as first-line treatment in patients with extensive-stage small cell lung cancer.
Study Start Date: Aug., 2026
Study Type: INTERVENTIONAL
Condition:
SCLC, Extensive Stage
Intervention:
DRUG: YL201
YL201 will be administered by intravenous i...